MCRB : Summary for Seres Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 1 hr.

Seres Therapeutics, Inc. (MCRB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.19-0.17 (-1.82%)
At close: 4:00PM EST
People also watch
ONCERDUSITCIALDRAXON
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close9.36
Open9.25
Bid9.01 x 200
Ask10.85 x 100
Day's Range9.09 - 9.41
52 Week Range8.05 - 35.98
Volume106,617
Avg. Volume193,208
Market Cap370.87M
BetaN/A
PE Ratio (TTM)-4.23
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire21 days ago

    Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences

    Seres Therapeutics Inc., , a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences:

  • Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session
    Zacks23 days ago

    Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session

    Seres Therapeutics, Inc. (MCRB) shares rose over 5% in the last trading session.

  • American City Business Journals24 days ago

    Seres finally explains 'poop pill' failure, reassuring investors

    For months, it’s been one of the biggest mysteries in biotech: Why did the most advanced treatment so far involving the so-called "human microbiome" fail in a mid-stage trial? Seres Therapeutics (MCRB) on Tuesday announced the findings from its analysis of the trial of SER-109, a drug that seeks to harness the microbiome — the trillions of bacteria living inside the human body — to treat a gastrointestinal disease. Seres officials said Tuesday that a misdiagnosis of certain patients in the trial meant that some participants did not actually have the disease, called Clostridium difficile infection, or C. diff.